中国现代医药杂志
中國現代醫藥雜誌
중국현대의약잡지
MODERN MEDICINE JOURNAL OF CHINA
2014年
4期
23-26
,共4页
邵剑锋%李曙平%练英妮%毛进星%莫月媚
邵劍鋒%李曙平%練英妮%毛進星%莫月媚
소검봉%리서평%련영니%모진성%막월미
鼻咽肿瘤%同期放化疗%尼妥珠单抗%奈达铂
鼻嚥腫瘤%同期放化療%尼妥珠單抗%奈達鉑
비인종류%동기방화료%니타주단항%내체박
Nasopharyngeal carcinoma%Concurrent chemoradiotherapy%Nimotuzumab%Nadaplatin
目的：评价局部晚期鼻咽癌患者应用尼妥珠单抗联合奈达铂同期放化疗治疗方案的临床疗效和安全性。方法48例局部晚期鼻咽癌患者，随机分成观察组24例，对照组24例。两组患者均接受常规放射治疗。对照组于放射治疗的第1天起静脉滴注奈达铂30mg/m2，每周1次，连续7周。观察组在奈达铂基础上联合尼妥珠单抗100mg，每周1次，连续7周。结果治疗结束后3个月，观察组与对照组鼻咽肿瘤完全缓解率分别为87.5%和66.7%（P=0.168），颈部淋巴结完全缓解率分别为90.9%和67.5%（P=0.062），差异无统计学意义。中位随访26个月后，观察组与对照组的2年总生存率分别为87.5%和79.1%（P=0.675），2年无瘤生存率分别为75.0%和70.8%（P=0.738），差异无统计学意义。两组治疗毒性无明显差异。结论局部晚期鼻咽癌患者在奈达铂同步放化疗基础上，加用尼妥珠单抗可改善近期疗效，同时耐受性好，远期疗效仍需进一步观察。
目的：評價跼部晚期鼻嚥癌患者應用尼妥珠單抗聯閤奈達鉑同期放化療治療方案的臨床療效和安全性。方法48例跼部晚期鼻嚥癌患者，隨機分成觀察組24例，對照組24例。兩組患者均接受常規放射治療。對照組于放射治療的第1天起靜脈滴註奈達鉑30mg/m2，每週1次，連續7週。觀察組在奈達鉑基礎上聯閤尼妥珠單抗100mg，每週1次，連續7週。結果治療結束後3箇月，觀察組與對照組鼻嚥腫瘤完全緩解率分彆為87.5%和66.7%（P=0.168），頸部淋巴結完全緩解率分彆為90.9%和67.5%（P=0.062），差異無統計學意義。中位隨訪26箇月後，觀察組與對照組的2年總生存率分彆為87.5%和79.1%（P=0.675），2年無瘤生存率分彆為75.0%和70.8%（P=0.738），差異無統計學意義。兩組治療毒性無明顯差異。結論跼部晚期鼻嚥癌患者在奈達鉑同步放化療基礎上，加用尼妥珠單抗可改善近期療效，同時耐受性好，遠期療效仍需進一步觀察。
목적：평개국부만기비인암환자응용니타주단항연합내체박동기방화료치료방안적림상료효화안전성。방법48례국부만기비인암환자，수궤분성관찰조24례，대조조24례。량조환자균접수상규방사치료。대조조우방사치료적제1천기정맥적주내체박30mg/m2，매주1차，련속7주。관찰조재내체박기출상연합니타주단항100mg，매주1차，련속7주。결과치료결속후3개월，관찰조여대조조비인종류완전완해솔분별위87.5%화66.7%（P=0.168），경부림파결완전완해솔분별위90.9%화67.5%（P=0.062），차이무통계학의의。중위수방26개월후，관찰조여대조조적2년총생존솔분별위87.5%화79.1%（P=0.675），2년무류생존솔분별위75.0%화70.8%（P=0.738），차이무통계학의의。량조치료독성무명현차이。결론국부만기비인암환자재내체박동보방화료기출상，가용니타주단항가개선근기료효，동시내수성호，원기료효잉수진일보관찰。
Objective To evaluate the efficacy and safety of nimotuzumab plus nadaplatin combined with concurrent chemoradiotherapy for locally advanced nasopharyngeal carcinoma. Methods A total of 48 patients with advanced nasopha-ryngeal carcinoma were randomized into the experimental group(n=24) and the control group(n=24). Radiotherapy was adminis-tered with the same way in both groups. The control group received nadaplatin 30mg/m 2 once a week for 7 weeks from the first day of radiotherapy. The experimental group was additionally given nimotuzumab 100mg once a week for 7 weeks on the basis of the control group. Results Three months after treatment,the complete response rate of the primary tumor in the experimental group and the control group were 87.5% and 66.7%(P=0.168),the complete response rate of the cervical lymph node were 90.9%and 67.5%(P=0.062). After a median follow-up of 26 months,the 2-year overall survival (OS) rate in the experimental group and the control group were 87.5%and 79.1%(P=0.675),the 2-year disease-free survival (DFS) were 75.0%and 70.8%(P=0.738). There was no significant difference between the two groups in the toxicity. Conclusion Nimotuzumab plus nadaplatin combined with concurrent chemoradiotherapy for locally advanced nasopharyngeal carcinoma is effective and tolerable. Long-term outcome need to be further investigated.
